PMID- 31440085
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal 
      chemotherapy in patients with advanced stage ovarian cancer: a single-center 
      experience.
PG  - 6931-6940
LID - 10.2147/CMAR.S213882 [doi]
AB  - OBJECTIVES: For patients with advanced ovarian cancer, neoadjuvant chemotherapy 
      (NACT) can significantly increase the rate of optimal cytoreduction. However, 
      this does not translate into a survival benefit. The aim of this study was to 
      investigate the feasibility and effect of neoadjuvant laparoscopic hyperthermic 
      intraperitoneal chemotherapy (NLHIPEC). METHODS: Between March 2016 and February 
      2018, 14 patients with advanced ovarian cancer who were not candidates for 
      optimal cytoreduction via primary debulking surgery (PDS) received NLHIPEC. Their 
      clinical data were retrospectively analyzed. RESULTS: No patients experienced 
      intraoperative complications during NLHIPEC. Grade 3 adverse events (AEs) were 
      noted in two (14.3%) patients, and all patients received planned NACT without 
      dose delay or dose reduction. Following NACT, CA125 levels <35 U/mL and <20 U/mL 
      were observed in six (42.9%) patients and five (35.7%) patients, respectively. 
      All patients underwent interval debulking surgery (IDS) after the last NACT 
      cycle. After IDS, R0 resection was achieved in 10 (71.4%) patients without 
      intraoperative injury, and one (7.1%) patient developed a grade 3 AE. During a 
      median follow-up time of 16 months, no patients died of disease, and the median 
      progression-free survival (PFS) was not achieved. Progression was noted in six 
      (42.9%) patients (range, 9-21 months). CONCLUSIONS: NLHIPEC appears to be a 
      feasible option for ovarian cancer patients who have a low likelihood of 
      achieving optimal cytoreduction during PDS.
FAU - Gao, Tian
AU  - Gao T
AUID- ORCID: 0000-0001-9446-5877
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
FAU - Huang, Xiao-Xin
AU  - Huang XX
AUID- ORCID: 0000-0003-3344-708X
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
FAU - Wang, Wu-Yun
AU  - Wang WY
AUID- ORCID: 0000-0001-6142-3099
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
AD  - Department of Gynecology, Hangzhou Women's Hospital, Hangzhou 310008, People's 
      Republic of China.
FAU - Wu, Miao-Fang
AU  - Wu MF
AUID- ORCID: 0000-0001-8201-960X
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
FAU - Lin, Zhong-Qiu
AU  - Lin ZQ
AUID- ORCID: 0000-0002-4751-109X
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
FAU - Li, Jing
AU  - Li J
AUID- ORCID: 0000-0003-1361-7790
AD  - Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen 
      University, Guangzhou 510120, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190724
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6664857
OTO - NOTNLM
OT  - hyperthermic intraperitoneal chemotherapy
OT  - laparoscopy
OT  - neoadjuvant
OT  - ovarian cancer
COIS- Dr Jing Li reports grants from the National Natural Science Foundation of China, 
      outside the submitted work. The authors report no other conflicts of interest in 
      this work.
EDAT- 2019/08/24 06:00
MHDA- 2019/08/24 06:01
PMCR- 2019/07/24
CRDT- 2019/08/24 06:00
PHST- 2019/04/29 00:00 [received]
PHST- 2019/07/09 00:00 [accepted]
PHST- 2019/08/24 06:00 [entrez]
PHST- 2019/08/24 06:00 [pubmed]
PHST- 2019/08/24 06:01 [medline]
PHST- 2019/07/24 00:00 [pmc-release]
AID - 213882 [pii]
AID - 10.2147/CMAR.S213882 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Jul 24;11:6931-6940. doi: 10.2147/CMAR.S213882. 
      eCollection 2019.